Xyotax STELLAR trial update
This article was originally published in Pharmaceutical Approvals Monthly
Cell Therapeutics' Xyotax (paclitaxel poliglumex) showed a statistically significant, 40% improvement in survival compared to vinorelbine for first-line treatment of poor performance status (PS2) non-small cell lung cancer in the firm's STELLAR 4 trial (n=32, p=0.012, hazard ratio 0.6), the firm says. On-study deaths also were significantly reduced compared to vinorelbine or gemcitabine. CTI previously reported that the 381-patient trial showed a non-significant increase in median survival compared to controls receiving either gemcitabine or vinorelbine (1Pharmaceutical Approvals Monthly May 2005, p. 4)...
You may also be interested in...
CTI’s repeated STELLAR trial failures to show Xyotax survival benefit for lung cancer could delay NDA submission. Detailed STELLAR 2 and 4 data showing equivalent survival with significant reductions in side effects compared to docetaxel or gemcitabine/vinorelbine will be presented in July
Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.
Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.